Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord blood-derived exosomes are extracellular vesicles isolated from the cord blood of healthy donors. These nano-sized vesicles serve as mediators of intercellular communication, carrying a complex cargo of proteins, lipids, and nucleic acids, including microRNAs. In the context of dry eye disease, these exosomes are being investigated for their potential anti-inflammatory and regenerative properties. They are hypothesized to modulate the ocular surface microenvironment, reduce inflammation, and promote the repair of corneal epithelial cells, thereby improving tear film stability and alleviating symptoms of dry eye. The research is currently in the preclinical stage, with studies conducted by Xi'an NO.1 Hospital.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord blood-derived exosomes.